Lipogems

Lipogems, based in Milan (IT) and Atlanta (USA), has developed an innovative treatment in the field of regenerative medicine, based on the use of adipose tissue.
The Lipogems treatment is applicable in several medical areas, including:

• Osteoarthritis treatment – orthopedics;
• Treatment of Crohn’s disease fistulas and diabetic foot ulcers;
• Drug delivery systems for oncology treatments.
  Currently, the company is focused on completing the preparatory steps for regulatory approval of the technology and its reimbursement process, both globally and especially in the US and Italy.
  In June 2022, the FDA authorized Lipogems to conduct two orthopedic clinical trials: Lipogems vs. Corticosteroids and Lipogems vs. Saline Solution. These are aimed at obtaining pre-market approval, a necessary prerequisite for reimbursement code assignment. Based on current progress, approval is expected in Q1 2026.